Europe Early Toxicity Testing Market Outlook – 2025
Toxicity testing is one of the crucial steps in the drug development process. The side effects of a chemical substance on the body could lead to chronic health conditions and it could do more damage to the body than good. Thus, early toxicity testing devices have gained demand for completing pre-clinical stages of drug development processes. What’s more, the failure of a potential drug candidate could cost millions to companies, making early toxicity testing more crucial than ever.

According to Allied Market Research, the Europe early toxicity testing market is expected to reach $460 million by 2025, growing at a CAGR of 7.1% from 2018 to 2025. Increase in adoption of the Vitro model, rise in demand for early toxicity testing and R&D activities in healthcare, and strict regulatory authorities regarding public healthcare welfare have boosted the growth of the market.

For years, toxicity testing relied on animal models that were used to extrapolate harmful events in humans. While these models proved to provide useful information about the effects of certain chemicals on the human body, they are expensive and often predict inconsistently human biology. Thus, over the last few years, several new initiatives gained attention and one of them is in vitro method.

Request for Sample Report for More Insights@ https://www.alliedmarketresearch.com/request-sample/5254
The vitro method allowed scientists to detect perturbations in cellular pathways that could result in harmful health effects. Moreover, the method is ideal for determining what could happen if the drug is taken in large doses.

Considering the cost of failure of drug candidates motivated the pharmaceutical companies to search for new ways to gain predictive testing methods. The in vitro and in vivo models offer significant advantages in drug development procedures, saving millions by predicting failure at an early stage. However, these methods require a huge amount of investment and studies in the candidate evaluation to avoid unnecessary spending of resources. While in vitro models will be used in the future during the drug development processes, the in vivo preclinical models would become standard for determining human risk.

The recent technological advancements have helped develop predictive models for early toxicity testing. The colossal data available to scientists and innovations in artificial intelligence and big data would unlock new doors in the future. Moreover, these technologies would cut down the cost of drug development as well as the time to bring the drug to the market. The in vitro and in vivo methods along will the innovative screening and computation methods would usher in a new and exciting era of predictive chemical toxicology.

Top Leading Players:
• Agilent Technologies, Inc
• General Electric Company (GE Healthcare)
• Danaher Corporation (Beckman Coulter, Inc.)
• Evotec AG (Cyprotex)
• Bioanalytical Systems, Inc
• BRUKER CORPORATION
• PerkinElmer Inc
• Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
• The Jackson Laboratory
• Thermo Fisher Scientific, Inc